Fludrocortisone
Brand names: Florinef
Fludrocortisone is a potent mineralocorticoid used (with a glucocorticoid) for replacement in adrenal insufficiency, and for some forms of postural (orthostatic) hypotension.
Adult dose
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
US labelling (FDA)
Reference — US labelling, may differ from UKDOSAGE AND ADMINISTRATION Dosage depends on the severity of the disease and the response of the patient. Patients should be continually monitored for signs that indicate dosage adjustment is necessary, such as remission or exacerbations of the disease and stress (surgery, infection, trauma) (see WARNINGS and PRECAUTIONS, General ). Addison's Disease In Addison's disease, the combination of fludrocortisone acetate tablets with a glucocorticoid such as hydrocortisone or cortisone provides substitution therapy approximating normal adrenal activity with minimal risks of unwanted effects. The usual dose is 0.1 mg of fludrocortisone acetate tablets daily, although dosage ranging from 0.1 mg three …
Source: US FDA prescribing information (openFDA / DailyMed), label dated 2025-05-19. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
- Systemic infections unless specific anti-infective therapy is employed
Side effects
- Hypokalaemia (very common); hypokalaemic alkalosis, decreased appetite (uncommon)
- Cardiac failure congestive (very common); cardiomegaly (uncommon)
- Hypertension (very common)
- Oedema, swelling (common)
- Headache (common); muscular weakness (common)
Interactions
- Amphotericin B or potassium-depleting diuretics (benzothiadiazines, ethacrynic acid, furosemide) - enhanced hypokalaemia
- Digitalis glycosides - enhanced possibility of arrhythmias or digitalis toxicity associated with hypokalaemia
- Oral anticoagulants - decreased prothrombin time response
- Antidiabetic drugs (oral agents and insulin) - diminished antidiabetic effect
- Barbiturates, phenytoin or rifampin - increased metabolic clearance of fludrocortisone acetate (hepatic enzyme induction)
Clinical monograph
How it works
It acts on mineralocorticoid receptors to promote renal sodium and water retention and potassium excretion, supporting blood pressure and electrolyte balance.
Prescribing in practice
- Monitor for sodium and fluid retention (oedema, raised blood pressure) and for low potassium.
- In adrenal insufficiency it is given alongside glucocorticoid replacement; do not omit doses during illness.
- Dose is titrated to blood pressure, postural symptoms and electrolytes.
Monitoring
Monitor blood pressure (lying and standing), electrolytes (sodium and potassium) and for fluid overload.
Counselling the patient
- Report ankle swelling, breathlessness or marked weakness.
- If you have adrenal insufficiency, do not miss doses and seek advice when unwell.
Evidence & guidelines
Standard mineralocorticoid replacement in adrenal insufficiency and an option for orthostatic hypotension.
Reference: Society for Endocrinology Addison's Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016